The heart and the gut.

The heart and the gut seem to be two organs that do not have much in common. However, there is an obvious and clinically relevant impact of gut functions on the absorption of drugs and oral therapies on the one hand. On the other hand, the gut determines the quantity of nutrient uptake and plays a central role in metabolic diseases. Patients with inflammatory bowel diseases appear to have a higher risk for coronary heart disease despite a lower prevalence of 'classical' risk factors, indicating additional links between the gut and the heart. However, they certainly have a 'leaky' intestinal barrier associated with increased permeability for bacterial wall products. An impaired intestinal barrier function will be followed by bacterial translocation and presence of bacterial products in the circulation, which can contribute to atherosclerosis and chronic heart failure (CHF) as recent data indicate. Impaired cardiac function in CHF vice versa impacts intestinal microcirculation leading to a barrier defect of the intestinal mucosa and increased bacterial translocation. These pathways and the most recent insights into the impact of the gut on acute and chronic heart disease will be discussed in this review.

[1]  Stephan von Haehling,et al.  Inflammatory mediators in chronic heart failure: an overview , 2004, Heart.

[2]  J. Danesh,et al.  Chronic infections and coronary heart disease: is there a link? , 1997, The Lancet.

[3]  P. Turnbaugh,et al.  The core gut microbiome, energy balance and obesity , 2009, The Journal of physiology.

[4]  D. Morel,et al.  Modulation of endotoxin-induced endothelial cell toxicity by low density lipoprotein. , 1986, Laboratory investigation; a journal of technical methods and pathology.

[5]  Yaoyu E. Wang,et al.  Alterations in diversity of the oral microbiome in pediatric inflammatory bowel disease , 2012, Inflammatory bowel diseases.

[6]  D. Gevers,et al.  Distinct microbiome in pouchitis compared to healthy pouches in ulcerative colitis and familial adenomatous polyposis , 2011, Inflammatory bowel diseases.

[7]  S. Anker,et al.  The gut and intestinal bacteria in chronic heart failure. , 2009, Current drug metabolism.

[8]  R. Sartor Genetics and environmental interactions shape the intestinal microbiome to promote inflammatory bowel disease versus mucosal homeostasis. , 2010, Gastroenterology.

[9]  Soo-Ho Choi,et al.  Low Doses of Lipopolysaccharide and Minimally Oxidized Low-Density Lipoprotein Cooperatively Activate Macrophages via Nuclear Factor &kgr;B and Activator Protein-1: Possible Mechanism for Acceleration of Atherosclerosis by Subclinical Endotoxemia , 2010, Circulation research.

[10]  M. Hirata,et al.  Statin regulation of CYP3A4 and CYP3A5 expression. , 2009, Pharmacogenomics.

[11]  D. Graham,et al.  Detection of Chlamydiae pneumoniae but Not Helicobacter pylori DNA in Atherosclerosis Plaques , 2003, Digestive Diseases and Sciences.

[12]  S. Anker,et al.  Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure. , 2002, The American journal of cardiology.

[13]  Kazuto Nakamura,et al.  Adiponectin Attenuates Lipopolysaccharide-Induced Acute Lung Injury through Suppression of Endothelial Cell Activation , 2012, The Journal of Immunology.

[14]  M. Nieminen,et al.  SEROLOGICAL EVIDENCE OF AN ASSOCIATION OF A NOVEL CHLAMYDIA, TWAR, WITH CHRONIC CORONARY HEART DISEASE AND ACUTE MYOCARDIAL INFARCTION , 1988, The Lancet.

[15]  Sharon I. Greenblum,et al.  Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease , 2011, Proceedings of the National Academy of Sciences.

[16]  E. Verrier,et al.  Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart. , 2004, The Journal of thoracic and cardiovascular surgery.

[17]  Christopher M O'Connor,et al.  Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. , 2003, JAMA.

[18]  D. Strachan,et al.  Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors , 1995, BMJ.

[19]  Josef Niebauer,et al.  Endotoxin and immune activation in chronic heart failure: a prospective cohort study , 1999, The Lancet.

[20]  G. Novo,et al.  Atherosclerosis, inflammation and Chlamydia pneumoniae. , 2009, World journal of cardiology.

[21]  A. Camm,et al.  Effect of Treatment for Chlamydia pneumoniae and Helicobacter pylori on Markers of Inflammation and Cardiac Events in Patients With Acute Coronary Syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA) , 2002, Circulation.

[22]  S. Anker,et al.  Plasma Cytokine Parameters and Mortality in Patients With Chronic Heart Failure , 2000, Circulation.

[23]  Haifeng Lu,et al.  Symbiotic gut microbes modulate human metabolic phenotypes , 2008, Proceedings of the National Academy of Sciences.

[24]  F. Hassan,et al.  Lipopolysaccharide and interferon‐γ enhance Fas‐mediated cell death in mouse vascular endothelial cells via augmentation of Fas expression , 2007, Clinical and experimental immunology.

[25]  R. Saggini,et al.  Botulinum Toxin in Cerebral Child Palsy , 2009, International journal of immunopathology and pharmacology.

[26]  H. Robenek,et al.  Endocytosis of oxidized LDL and reversibility of migration inhibition in macrophage-derived foam cells in vitro. A mechanism for atherosclerosis regression? , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[27]  P. Tothill,et al.  Acetaminophen absorption and metabolism in celiac disease and Crohn's disease , 1981, Clinical pharmacology and therapeutics.

[28]  K. Walley,et al.  Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflammatory response. , 2006, Cardiovascular research.

[29]  H. Niwa,et al.  Alteration of histamine, serotonin and primary prostaglandin in case of diarrhea induced by endotoxin and gastrointestinal absorption of drug. , 1985, Journal of pharmacobio-dynamics.

[30]  D. Schwartz,et al.  Toll-like receptor 4 polymorphisms and atherogenesis. , 2002, The New England journal of medicine.

[31]  Haichang Wang,et al.  Lipopolysaccharide up-regulates the expression of Fcalpha/mu receptor and promotes the binding of oxidized low-density lipoprotein and its IgM antibody complex to activated human macrophages. , 2010, Atherosclerosis.

[32]  Dan Turner,et al.  Alterations in the gut microbiome of children with severe ulcerative colitis , 2012, Inflammatory bowel diseases.

[33]  W. Coyle,et al.  The microbiome and obesity: Is obesity linked to our gut flora? , 2009, Current gastroenterology reports.

[34]  K. Mccafferty,et al.  Intestinal Microbiota Determine Severity of Myocardial Infarction in Rats , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  I-Min A. Chen,et al.  IMG/M-HMP: A Metagenome Comparative Analysis System for the Human Microbiome Project , 2012, PloS one.

[36]  P. Poole‐Wilson,et al.  Cellular endotoxin desensitization in patients with severe chronic heart failure , 2005, European journal of heart failure.

[37]  L. Badimón,et al.  Lipopolysaccharide downregulates CD91/low-density lipoprotein receptor-related protein 1 expression through SREBP-1 overexpression in human macrophages. , 2013, Atherosclerosis.

[38]  M. Cernadas It takes a microbiome: commensals, immune regulation, and allergy. , 2011, American journal of respiratory and critical care medicine.

[39]  V. Valtonen,et al.  Infection as a risk factor for infarction and atherosclerosis. , 1991, Annals of medicine.

[40]  J. Flier,et al.  Gut Check: Testing a Role for the Intestinal Microbiome in Human Obesity , 2009, Science Translational Medicine.

[41]  J E Parrillo,et al.  Myocardial dysfunction in septic shock: Part I. Clinical manifestation of cardiovascular dysfunction. , 2001, Journal of cardiothoracic and vascular anesthesia.

[42]  Guansong Wang,et al.  Protection from lipopolysaccharide-induced pulmonary microvascular endothelial cell injury by activation of hedgehog signaling pathway , 2011, Molecular Biology Reports.

[43]  C. Lang,et al.  Decreased intestinal CYP3A in celiac disease: Reversal after successful gluten‐free diet: A potential source of interindividual variability in first‐pass drug metabolism , 1996, Clinical pharmacology and therapeutics.

[44]  D. Kelly,et al.  Toll-like Receptor-mediated Inflammatory Signaling Reprograms Cardiac Energy Metabolism by Repressing Peroxisome Proliferator-activated Receptor ␥ Coactivator-1 Signaling Clinical Perspective on P 482 Methods Animal Experiments and Generation Results Lps Stimulation Suppresses Cardiac Mitochondrial , 2022 .

[45]  A. Dubin,et al.  Gastric intramucosal pH as a therapeutic index of tissue oxygenation in critically ill patients , 1992, The Lancet.

[46]  G. Wilkinson Cytochrome P4503A (CYP3A) metabolism: Prediction ofIn Vivo activity in humans , 1996, Journal of Pharmacokinetics and Biopharmaceutics.

[47]  J. Lovegrove,et al.  The type and quantity of dietary fat and carbohydrate alter faecal microbiome and short-chain fatty acid excretion in a metabolic syndrome ‘at-risk’ population , 2013, International Journal of Obesity.

[48]  S. Kiechl,et al.  Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. , 1999, Journal of the American College of Cardiology.

[49]  R. Neubig,et al.  Phagocyte-derived catecholamines enhance acute inflammatory injury , 2007, Nature.

[50]  N. Khardori Exposure to Environmental Microorganisms and Childhood Asthma , 2011 .

[51]  Katherine H. Huang,et al.  Structure, Function and Diversity of the Healthy Human Microbiome , 2012, Nature.

[52]  S. Mazmanian,et al.  The gut microbiota shapes intestinal immune responses during health and disease , 2009, Nature Reviews Immunology.

[53]  D. Hommes,et al.  Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn's disease Published, JLR Papers in Press, September 22, 2007. , 2007, Journal of Lipid Research.

[54]  D. Acuña-Castroviejo,et al.  Synergism between melatonin and atorvastatin against endothelial cell damage induced by lipopolysaccharide , 2011, Journal of pineal research.

[55]  R. Serov,et al.  Collagen accumulation and dysfunctional mucosal barrier of the small intestine in patients with chronic heart failure. , 2008, International Journal of Cardiology.

[56]  R. Terkeltaub,et al.  Oxidized LDL enhances lipopolysaccharide-induced tissue factor expression in human adherent monocytes. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[57]  E. Porat,et al.  Cardiomyocyte Toll-like receptor 4 is involved in heart dysfunction following septic shock or myocardial ischemia. , 2010, Journal of molecular and cellular cardiology.

[58]  J. Neu,et al.  The developing intestinal microbiome and its relationship to health and disease in the neonate , 2011, Journal of Perinatology.

[59]  H. Ogawa,et al.  Potential association of Helicobacter cinaedi with atrial arrhythmias and atherosclerosis , 2012, Microbiology and immunology.

[60]  G. Schiavoni,et al.  Chlamydia Pneumoniae and Atherosclerosis: Current State and Future Prospectives , 2009, International journal of immunopathology and pharmacology.

[61]  P. Poole‐Wilson,et al.  Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. , 1997, The American journal of cardiology.

[62]  M. Farkouh,et al.  Are patients with inflammatory bowel disease at increased risk of coronary artery disease? , 2012, The American journal of medicine.

[63]  P. Poole‐Wilson,et al.  Altered intestinal function in patients with chronic heart failure. , 2007, Journal of the American College of Cardiology.

[64]  Arthur Kaser,et al.  Gut microbiome, obesity, and metabolic dysfunction. , 2011, The Journal of clinical investigation.

[65]  E. Porat,et al.  Toll-like receptor 4 stimulation initiates an inflammatory response that decreases cardiomyocyte contractility. , 2011, Antioxidants & redox signaling.

[66]  L. Campbell,et al.  Chlamydia pneumoniae — an infectious risk factor for atherosclerosis? , 2004, Nature Reviews Microbiology.

[67]  Qingbo Xu,et al.  Infections, immunity, and atherosclerosis: associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis. , 2000, Circulation.

[68]  Brian J. Bennett,et al.  Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease , 2011, Nature.

[69]  L. Fulton,et al.  Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. , 2008, Cell host & microbe.

[70]  T. Finkel,et al.  The role of infection in restenosis and atherosclerosis: focus on cytomegalovirus , 1996, The Lancet.

[71]  J E Parrillo,et al.  Myocardial dysfunction in septic shock. , 2000, Critical care clinics.

[72]  E. Mardis,et al.  An obesity-associated gut microbiome with increased capacity for energy harvest , 2006, Nature.

[73]  M. Färkkilä,et al.  Increased risk for coronary heart disease, asthma, and connective tissue diseases in inflammatory bowel disease. , 2011, Journal of Crohn's & colitis.

[74]  R. Beale,et al.  Assessment of Splanchnic Oxygenation by Gastric Tonometry in Patients with Acute Circulatory Failure , 1994 .

[75]  P. Bork,et al.  A human gut microbial gene catalogue established by metagenomic sequencing , 2010, Nature.

[76]  O. Febo,et al.  Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. , 1995, Circulation.

[77]  R. Knight,et al.  The Effect of Diet on the Human Gut Microbiome: A Metagenomic Analysis in Humanized Gnotobiotic Mice , 2009, Science Translational Medicine.

[78]  Xianzhong Meng,et al.  Toll-like receptor 4 mediates oxidized - LDL induced macrophage differentiation to foam cells , 2010 .

[79]  Ruth E Ley,et al.  Obesity and the human microbiome , 2010, Current opinion in gastroenterology.

[80]  S. Anker,et al.  The importance of the gastrointestinal system in the pathogenesis of heart failure. , 2005, European heart journal.

[81]  S. Anker,et al.  The emerging role of the gut in chronic heart failure , 2008, Current opinion in clinical nutrition and metabolic care.

[82]  E. Gurfinkel,et al.  Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study , 1997, The Lancet.

[83]  K. Werdan,et al.  Cardiodepression by tumor necrosis factor-alpha. , 1999, European cytokine network.

[84]  N. Zhang,et al.  Lipopolysaccharide induces endothelial cell apoptosis via activation of Na(+)/H(+) exchanger 1 and calpain-dependent degradation of Bcl-2. , 2012, Biochemical and biophysical research communications.

[85]  A. Thompson Developmental origins of obesity: Early feeding environments, infant growth, and the intestinal microbiome , 2012, American journal of human biology : the official journal of the Human Biology Council.

[86]  B. Melichar,et al.  Intestinal Permeability and Vitamin A Absorption in Patients With Chemotherapy-Induced Diarrhea , 2008, American journal of clinical oncology.

[87]  Samantha A. Tavener,et al.  Immune Cell Toll-Like Receptor 4 Is Required for Cardiac Myocyte Impairment During Endotoxemia , 2004, Circulation research.

[88]  J. Mazière,et al.  Lipopolysaccharide enhances oxidative modification of low density lipoprotein by copper ions, endothelial and smooth muscle cells. , 1999, Atherosclerosis.

[89]  G. Schuler,et al.  Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure , 2003, European journal of heart failure.

[90]  J. Parrillo,et al.  Myocardial dysfunction in septic shock: Part II. Role of cytokines and nitric oxide. , 2001, Journal of cardiothoracic and vascular anesthesia.

[91]  P. Ferdinandy,et al.  Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction. , 2003, Cardiovascular research.

[92]  Julia Oh,et al.  Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis , 2012, Genome research.